| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥924.6B | ¥892.9B | +3.6% |
| Operating Income | ¥46.1B | ¥31.1B | +47.9% |
| Ordinary Income | ¥51.0B | ¥37.5B | +35.8% |
| Net Income | ¥41.2B | ¥24.4B | +68.9% |
| ROE | 3.0% | 1.8% | - |
FY2026 Q3 results show Kyorin Pharmaceutical achieving revenue of 92.5B yen (YoY +3.6%), operating income of 4.6B yen (YoY +47.9%), ordinary income of 5.1B yen (YoY +35.8%), and net income of 4.1B yen (YoY +68.9%). The significant profit improvement was driven by enhanced gross margins at 42.8% and contributions from non-operating gains including investment securities sales gains of 0.4B yen and dividend income of 0.5B yen. While revenue growth remains modest at 3.6%, operating profit expansion of 47.9% demonstrates improved cost management. However, the full-year forecast indicates operating income declining 51.5% YoY to 6.1B yen, suggesting Q3 results benefited from temporary factors. Financial position remains solid with current ratio of 413.9% and debt-to-capital ratio of 17.4%, though working capital efficiency shows significant deterioration with DSO at 178 days and inventory turnover at 182 days.
[Profitability] ROE of 3.0% reflects limited return on equity despite profit improvement, with net profit margin at 4.5% and operating margin at 5.0% showing room for improvement relative to historical levels. Financial leverage of 1.40x remains conservative. Interest coverage ratio stands at 25.05x indicating strong debt servicing capability with interest expenses of 0.2B yen well covered by operating profit. The tax burden ratio of 0.746 and effective tax rate of 25.4% are within normal ranges. [Cash Quality] Cash and deposits of 14.0B yen provide coverage of 1.54x against short-term borrowings of 9.1B yen, indicating adequate liquidity for near-term obligations. Working capital efficiency has deteriorated significantly with DSO extending to 178 days, inventory turnover at 182 days, and cash conversion cycle of 575 days, suggesting substantial delays in cash realization from operations. [Investment Efficiency] Asset turnover of 0.476x demonstrates moderate asset utilization. ROIC metrics indicate returns below optimal levels given the extended working capital cycle. [Financial Health] Equity ratio of 71.5% reflects strong capitalization and conservative financial structure. Current ratio of 413.9% and quick ratio of 335.3% indicate robust short-term liquidity. Total interest-bearing debt of 29.2B yen against equity of 138.9B yen results in debt-to-equity ratio of 0.21x, maintaining low leverage. Debt-to-capital ratio of 17.4% confirms conservative capital structure with ample debt capacity.
Cash and deposits of 14.0B yen represent a baseline liquidity position adequate for covering short-term debt obligations of 9.1B yen with 1.54x coverage. The balance sheet reveals significant working capital challenges with accounts receivable of 45.2B yen and inventories of 26.4B yen representing substantial capital tied up in operations. Accounts payable of 23.8B yen provides partial offset through supplier credit. The extended DSO of 178 days and inventory days of 182 days indicate prolonged conversion cycles from operations to cash, suggesting either collection difficulties, generous customer payment terms, or potential demand forecasting issues. Total current assets of 139.2B yen against current liabilities of 33.6B yen demonstrate strong liquidity cushion despite working capital inefficiencies. The reduction in treasury stock book value from 17.3B yen to 5.9B yen during the period suggests potential share cancellation or disposal activities, representing a shift in capital allocation policy. With dividend payout ratio calculated at approximately 83.0% based on quarterly earnings run-rate, cash generation capability becomes critical for sustaining distributions, though current liquidity position provides near-term support.
Ordinary income of 5.1B yen versus operating income of 4.6B yen shows net non-operating contribution of approximately 0.5B yen, comprising primarily dividend income of 0.5B yen and minimal net financial costs given interest expenses of 0.2B yen. Additionally, extraordinary gains from investment securities sales of 0.4B yen contributed to net income expansion. Non-operating and extraordinary items represent approximately 1.0% of revenue from financial income and securities gains, indicating partial reliance on investment-related returns beyond core operations. The substantial 68.9% increase in net income compared to 47.9% operating income growth reflects both non-operating gains and tax effects supporting bottom-line performance. Working capital quality indicators raise concerns as extended receivables turnover of 178 days and inventory turnover of 182 days significantly exceed typical pharmaceutical industry norms, suggesting either business model characteristics or operational efficiency challenges. The cash conversion cycle of 575 days indicates nearly 1.6 years required to convert investments in operations back to cash, which could signal earnings quality issues if accounts receivable or inventory contain aged or impaired items. Without operating cash flow data disclosed for the quarter, direct verification of cash-backed earnings remains limited, though the deteriorating working capital metrics warrant attention regarding the sustainability of reported profits.
Working capital deterioration poses significant cash generation risk, with DSO of 178 days and inventory turnover of 182 days creating cash conversion cycle of 575 days, substantially constraining liquidity generation despite reported profit improvements and potentially masking collection or inventory obsolescence issues.
High dividend payout ratio of approximately 83.0% based on quarterly earnings run-rate limits financial flexibility and internal capital accumulation, creating sustainability concerns if operating cash flow generation fails to improve alongside working capital efficiency deterioration.
Revenue growth constraints evident in modest 3.6% YoY increase and full-year forecast indicating 2.4% revenue decline suggest limited top-line momentum, while full-year operating income guidance of 6.1B yen represents 51.5% decline YoY, indicating Q3 profit expansion may derive from temporary factors including investment securities gains rather than sustainable operational improvements.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: Operating margin 5.0% substantially exceeds industry median of -218.2% (Q3 2025), indicating Kyorin maintains positive operational profitability while many pharmaceutical peers report significant losses. Net profit margin of 4.5% similarly outperforms industry median of -216.8%, positioning the company among profitable operators. ROE of 3.0% significantly exceeds industry median of -35.8%, though absolute ROE level remains modest. ROA of 2.1% compares favorably to industry median of -23.9%.
Financial Health: Equity ratio of 71.5% aligns closely with industry median of 67.8% (IQR: 62.1%-79.1%), indicating comparable capital structure conservatism. Current ratio of 413.9% falls below industry median of 662% but remains within healthy liquidity range. Financial leverage of 1.40x approximates industry median of 1.47x, confirming typical sector capitalization structure.
Efficiency: Asset turnover of 0.476x substantially exceeds industry median of 0.17x, demonstrating superior asset utilization relative to peers. However, receivables turnover of 178 days extends beyond industry median of 151.55 days, and inventory turnover of 182 days compares unfavorably to median of 281.61 days when adjusted for direction, indicating working capital efficiency challenges. Operating working capital turnover cycle substantially exceeds industry median of 148.78 days, confirming relative inefficiency in working capital management.
Growth: Revenue growth of 3.6% YoY outperforms industry median decline of -12.5%, positioning Kyorin among growth-oriented pharmaceutical companies in a contracting sector environment.
(Industry: Pharmaceutical sector, N=13 companies for most metrics, Comparison period: Q3 2025, Source: Proprietary analysis)
First, the significant profit margin improvement with operating income growth of 47.9% outpacing revenue growth of 3.6% demonstrates effective operational leverage and cost management, though sustainability requires monitoring given full-year guidance indicating 51.5% operating income decline, suggesting Q3 benefited from temporary factors including 0.4B yen investment securities gains. The company maintains positive profitability substantially outperforming pharmaceutical industry peers where median operating and net margins remain deeply negative, indicating relative competitive positioning strength or business model differentiation.
Second, working capital efficiency deterioration represents the most critical operational concern, with cash conversion cycle of 575 days and receivables turnover of 178 days signaling substantial delays in converting sales to cash. This working capital intensity substantially exceeds pharmaceutical industry norms and creates latent cash flow pressure despite reported profit improvements, requiring operational process improvements in collections and inventory management to unlock trapped capital.
Third, the combination of high dividend payout ratio at 83.0% and robust financial position with equity ratio of 71.5%, current ratio of 413.9%, and interest coverage of 25.05x presents mixed signals: while near-term dividend sustainability appears supported by strong balance sheet liquidity, the elevated payout ratio limits capital reinvestment flexibility and creates vulnerability if operating cash generation fails to improve alongside working capital efficiency challenges.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.